연구개발

전문가와 협업을 통해 다양한 R&D에 투자 함으로써 언제나 더 나은 미래를 모색 합니다.

Pipeline

개발현황

  • Formulation (14)
  • Pre-Clinical(1)
  • Phase 1 (5)
  • Phase 2
  • Phase 3 (1)
  • NDA (2)
    • UI093
    • UI106
    • UI105
    • UI070,UI071
    • UI087,UI088
    • UI083
    • UI110
    • UI109
    • UI094
    • UI066
    • UI060
    • UI117
    • UI110
    • UI009
    • UI100
    • UI111
    • UI059
    • UI064
    • -
    • UI064
    • UI022,UI023
  • Controlled Release (4)
  • FDC (14)
  • BA Improvement (-)
  • DPI (2)
  • New Salt (-)
  • New Use (-)
  • ETC (1)

발매일정 - 장기계획

  • 2025

    • UI093(Lipid modifying agent)

      New Combination

    • UI022, UI023(Platelet aggregation inh.)

      New Combination

    • UI009(COPD)

      New Combination

    • UI100(Lipid modifying agent)

      New Combination

  • 2026

    • UI0111(Lipid modifying agent)

      New Combination

    • UI105(Anticancer)

      Injection

    • UI087, UI088(Antidiabetics)

      New Combination

    • UI106(Asthma, COPD)

      Inhaler

    • UI070, UI071(Antidiabetics)

      New Combination

    • UI059(GERD)

      New Combination

  • 2027

    • UI110(Bronchitis)

      New Combination

    • UI109(BPH)

      New Combination

    • UI083(GERD)

      New Combination

    • UI064(Allergic rhinitis)

      New Combination

  • 2028

    • UI094(GERD)

      New dosage form

  • 2030

    • UI066(Vasodilators)

      New dosage form

  • 수립예정

    • UI060(NSAIDs)

      New Combination

    • UI117(Alopecia)

      New dosage form

개인정보처리방침

개인정보처리방침